Citadel Advisors
RXST icon

Citadel Advisors’s RxSight RXST Stock Holding History

Citadel Advisors’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$246K Buy
40,000
+25,400
+174% +$211K ﹤0.01% 10948
2025
Q4 		$152K Sell
14,600
-18,100
-55% -$182K ﹤0.01% 11303
2025
Q3 		$294K Buy
32,700
+9,100
+39% +$79.9K ﹤0.01% 10414
2025
Q2 		$307K Buy
23,600
+15,100
+178% +$227K ﹤0.01% 9762
2025
Q1 		$215K Sell
8,500
-200
-2% -$5.94K ﹤0.01% 10318
2024
Q4 		$299K Sell
8,700
-1,300
-13% -$58.6K ﹤0.01% 9652
2024
Q3 		$494K Buy
10,000
+5,200
+108% +$266K ﹤0.01% 8282
2024
Q2 		$289K Buy
4,800
+2,800
+140% +$160K ﹤0.01% 9220
2024
Q1 		$103K Sell
2,000
-800
-29% -$39.3K ﹤0.01% 11318
2023
Q4 		$113K Buy
2,800
+700
+33% +$20.5K ﹤0.01% 10776
2023
Q3 		$58.6K Sell
2,100
-1,300
-38% -$38.8K ﹤0.01% 11566
2023
Q2 		$97.9K Sell
3,400
-3,600
-51% -$80.1K ﹤0.01% 10973
2023
Q1 		$117K Buy
7,000
+6,000
+600% +$84.7K ﹤0.01% 11044
2022
Q4 		$12.7K Buy
+1,000
New +$12.2K ﹤0.01% 13491

Other funds holding RXST

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
NSGL
No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Citadel Advisors's RXST Position: Q1 2026 in Review

Citadel Advisors increased its RxSight (RXST) stake by 7% in Q1 2026, buying an estimated $605K and bringing the position to 1,118,719 shares worth $6.89M. The position accounts for ﹤0.01% of the portfolio, ranked #3834.

Citadel Advisors first reported a position in RXST in Q2 2022 and has held it in 16 quarters since. The position peaked at $34.2M in Q4 2024. 164 funds tracked by Wall St. Rank hold RXST as of Q1 2026.

  • Citadel Advisors held 1,118,719 shares of RxSight worth $6.89M as of Q1 2026.
  • Citadel Advisors bought 72,897 RxSight shares in Q1 2026, an estimated $605K.
  • RxSight made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3834 holding.
  • Citadel Advisors first reported a position in RxSight in Q2 2022 and has held it in 16 quarters since.
  • Citadel Advisors's RxSight position peaked at $34.2M in Q4 2024.
  • 164 funds tracked by Wall St. Rank held RxSight as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.